Abstract: Compounds and pharmaceutical compositions for use in the treatment and/or prophylaxis of cartilage and/or bone conditions and for methods of treating such condition. The compounds are salts of strontium that have a water-solubility of from about 1 g/l to about 100 g/l at room temperature, especially amino acid salts of strontium or dicarboxylic acid salts of strontium. Examples of novel water-soluble strontium salts are e.g. strontium glutamate and strontium alpha-ketoglutarate. The present invention also relates to an improved method for preparing the strontium salt of glutamic acid.

Abstract: The present invention relates to substituted thienyl- and furanyl-isoquinolinones that act, for example, as modulators of poly(ADP-ribose) polymerase (PARP). The present invention also relates to processes for the preparation of substituted thienyl and furanyl-isoquinolinones and to their use in treating various diseases and disorders.

Abstract: The present invention relates to a kit of parts comprising a GLP-1 molecule and an anti-emetic drug, said kit of parts being suitable for separate, sequential or/and simultaneous administration to a subject, preferably a human being. Also provided are combinations of GLP-1 or a GLP-1 analog with one or more anti-emetic drugs, as well as uses of the combinations in the manufacture of medicaments.

Abstract: Compounds and pharmaceutical compositions for use in the treatment and/or prophylaxis of cartilage and/or bone conditions and for methods of treating such condition. The compounds are salts of strontium that have a water-solubility of from about 1 g/l to about 100 g/l at room temperature, especially amino acid salts of strontium or dicarboxylic acid salts of strontium. Examples of novel water-soluble strontium salts are e.g. strontium glutamate and strontium alpha-ketoglutarate. The present invention also relates to an improved method for preparing the strontium salt of glutamic acid.

Abstract: An apparatus and method for using the apparatus is taught for decreasing the density of and feeding into a convention small baler agricultural crop product that has been compressed into two or more flakes, the flakes having been then further compressed into a large bale, the apparatus comprising a material bed and pusher assembly; a staging area; a set of feeder rollers; a set of drawing rollers; a metering assembly; a chaff discharge system; and a small baler. A method of using the apparatus is also taught. Baled agricultural crop product that is passed through the taught apparatus and method indistinguishably resembles agricultural crop product that has never been baled.

Abstract: A controlled release pharmaceutical composition comprising a strontium salt. The invention also relates to the use of a strontium salt for treating a male suffering from diseases and conditions affecting metabolism and/or structural integrity of cartilage and/or bone. The invention also relates to the use of a strontium-containing compound for preventing a cartilage and/or bone condition in a subject, and for the treatment and/or prophylaxis of secondary osteoporosis.

Abstract: The present invention relates to molecules, compositions and methods suitable for the treatment or prevention of biliary dyskinesia and/or pain and/or discomfort originating from the biliary tree. The peptide hormone glucagon-like peptide-1 (GLP-1) has both anti-secretory effects and smooth muscle relaxatory properties in the gastrointestinal tract. GLP-1 exists in several forms, where the natural occurring GLP-1 molecules are GLP-1 (1-37), GLP-1 (7-37), and the amidated versions GLP-1 (1-36)amide, GLP-1 (7-36)amide. Other molecules capable of binding to and activating the GLP-1 receptor is herein included in the tern GLP-1 molecules. GLP-1 molecules may be naturally occurring or homologues of GLP-1 having one or more amino acid substitutions or modifications. The GLP-1 molecules are used for the manufacture of a medicament for the treatment or prevention of biliary dyskinesia and/or pain and/or discomfort originating from the biliary tree.

Abstract: A disposable cartridge (10), which is suitable for use in a process of preparing a beverage, comprises a pump unit (1). A duct system (30) of the pump unit (1) has a first duct (31) and a second duct (32) which merges into the first duct (31), wherein an angle (?) between the ducts (31, 32) is considerably smaller than 90°. In a process of preparing a beverage, a first fluid is supplied by an inlet portion of the first duct (31), and a flow of a second fluid is supplied by the second duct (32). At the position where the ducts (31, 32) meet; a transfer of momentum from the flow of the second fluid to the first fluid takes place, so that an underpressure is obtained, as a result of which the first fluid is put in motion. Furthermore, a joint flow of the first fluid and the second fluid is obtained in an outlet portion of the first duct (31).

Abstract: Improved treatments of joint diseases, such as, e.g.

Abstract: Methods for improving pain management in a mammal, the methods comprising administering a combination of a strontium-containing compound and a second therapeutically and/or prophylactically active substance selected from the group consisting of analgesic agents, anti-inflammatory agents and palliative agents to the mammal. Pharmaceutical compositions for use in such methods, comprising a strontium-containing compound and a second therapeutically and/or prophylactically active substance selected from the group consisting of analgesic agents, anti-inflammatory agents and palliative agents.

Abstract: A steam powered engine system wherein hot exhaust gas produced by a small secondary engine is used to heat water to a temperature above 212 degrees F., the superheated water being injected into a cylinder containing hot compressed gas. The water then flash expands into steam to drive a piston. The hot exhaust gas from the secondary engine is further utilized to scavenge spent gas and liquid from the cylinder during the return stroke of the piston, as well as to maintain a suitably high temperature within the cylinder.

Abstract: A method for the treatment and/or prophylaxis of an ostenonecrotic bone disease in a mammal in need thereof, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia/osteonecrosis, Legg-Calve-Perthes disease and femoral head necrosis, the method comprising administering an effective dose of a strontium-containing compound (a) to the mammal. A method for the treatment and/or prophylaxis of an osteonecrotic bone disease, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia/osteonecrosis and femoral head necrosis, in a mammal who is to be or is treated with a therapeutic agent (b) known to or suspected of inducing apoptosis and/or necrosis of bone cells, the method comprising administering a strontium-containing compound (a) in combination with (b).

Abstract: A method for frame and frequency synchronization of an OFDM signal and a signal for transmitting an OFDM signal is described, the purpose of which is to impress a pilot phase profile that is then used at the receiving end for frame and frequency synchronization on pilots which are already contained in the OFDM signal for channel estimation. This has the advantage that no additional transmission capacity has to be used for the synchronization. The method according to the present invention is initiated by a rough time synchronization unit connected upline, which searches for the beginning of the guard interval in the OFDM signal. The comparison between a stored pilot phase profile and the received subcarrier symbol is performed using a cross-correlation, whose result is then evaluated to determine the frame and frequency synchronization.

Abstract: The invention relates to a method for producing a fluid conduit, in particular a fluid conduit for a CO2 refrigerating plant. The aim of said invention is to develop a quick and inexpensive method. For this purpose, several pipes (5-9) are simultaneously supplied by means of at least one roller (11) which is provided with peripheral grooves (14) and are helically wound in a parallel direction with respect to each other, wherein each pipe (5-9) is guided along a helical line and the helical lines of all pipes (5-9) are parallel to each other.

Abstract: The invention relates to polypeptide conjugates comprising a polypeptide exhibiting G-CSF activity and having an amino acid sequence that differs from the amino acid sequence of human G-CSF in at least one specified introduced and/or removed amino acid residue comprising an attachment group for a non-polypeptide moiety, and having at least one non-polypeptide moiety attached to an attachment group of the polypeptide. The attachment group may e.g. be a lysine, cysteine, aspartic acid or glutamic acid residue or a glycosylation site, and the non-polypeptide moiety may e.g. be a polymer such as polyethylene glycol or an oligosaccharide. The conjugate, which has a reduced in vitro bioactivity compared to hG-CSF, has one or more improved properties such as increased biological half-life and increased stimulation of neutrophils.

Abstract: The present invention relates, in one aspect, to the use of a secretagogue compound for the preparation of a medicament for the prophylaxis or treatment of cancer cachexia in an individual in need of such treatment. In another aspect, the present invention relates to the use of a ghrelin-like compound for the preparation of a medicament for prophylaxis or treatment of cachexia in an individual by administering a subcutaneous dosage of said medicament to the individual. In a further aspect, the present invention relates to the use of a ghrelin-like compound or a pharmaceutically acceptable salt thereof for the preparation of a medicament for stimulation of appetite in an individual by administering a subcutaneous dosage of said medicament to the individual. Furthermore, the present invention relates to a number of new ghrelin-like compounds and uses thereof, as well as to pharmaceutical compositions and medical packaging comprising the new ghrelin-like compounds.

Abstract: Disclosed is a method for producing an HTSC band on a substrate band, for example, a strong bond being created between the substrate band and the band as a result of the production process (e.g. PVD process or galvanic deposition). According to the invention, separation of the highly adhesive band from the substrate band is aided by the fact that the substrate band is made of a shape memory alloy, the shape memory of the band being activated in a separating device by heating and, possibly, cooling. Tension-related stress is generated in the joint on the boundary surface between the bands as a result of the substrate being deformed such that separation of the band from the substrate band is aided or even caused. Also disclosed is a production facility in which the substrate band is made of a shape memory alloy.

Abstract: The present invention relates to a method of manufacturing tearable sheets, wherewith each sheet obtains a perfectly smooth tear edge when torn-off. The method comprises the steps of: punching each sheet transversely of the fibers of said sheet from a first side of the sheet to an extend corresponding to a firs portion of the thickness of the sheet; and punching each sheet transversely of the fibers of said sheet from a second side of the sheet to an extent corresponding to a second portion of the thickness of said sheet; wherein the sum of said first thickness portion and said second thickness portion is smaller than the thickness of the sheet, and wherein the second punching operation is performed parallel with the first punching operation but displaced in a plane parallel with said first and said second sides of the sheet, said displacement being adapted for tear-off purposes.

Abstract: A medical diagnostic apparatus including a display screen for displaying a graphical user interface (GUI) including virtual switches, a user input device for allowing the virtual switches of the GUI to be selected, a processor connected to the display screen and the user input device, and a computer program having alphanumeric input instructions that cause the processor to display one of a numeric entry GUI and an alphanumeric entry GUI on the display screen. Selecting a predetermined virtual switch of the numeric GUI using the input device causes the alphanumeric GUI to be displayed, while selecting a predetermined virtual switch of the alphanumeric GUI causes the numeric GUI to be displayed.

Abstract: Polypeptide conjugates with G-CSF activity comprising a polypeptide having at least one introduced lysine residue and at least one removed lysine residue compared to the sequence of human G-CSF, and which are conjugated to 2-6 polyethylene glycol moieties. The conjugates have a low in vitro bioactivity, a long in vivo half-life, a reduced receptor-mediated clearance, and provide a more rapid stimulation of production of white blood cells and neutrophils than non-conjugated recombinant human G-CSF.